Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Florence Marteau"'
Autor:
Toni K. Choueiri, Michael J. Morris, Jie Meng, Aaron D. Falchook, Darren R. Feldman, Johanna Lister, Ronald C. Chen, Marion Feuilly, Daniel J. George, Florence Marteau
Publikováno v:
Cancer
Background Cabozantinib Versus Sunitinib as Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial (CABOSUN) was a randomized, open‐label, phase 2 trial evaluating
Autor:
Kimberly Webster, Sara Shaunfield, Karen Kaiser, Marion Feuilly, David Cella, Daniel M. Halperin, James C. Yao, Leilani Lacson, Al B. Benson, George J. Greene, Florence Marteau, Susan Yount, Simron Singh
Publikováno v:
Neuroendocrinology. 111:850-862
Objective: To develop a symptom-focused index to evaluate representative symptoms, treatment side effects, and emotional and functional well-being of patients with carcinoid syndrome (CS). Methods: The development of the Functional Assessment of Canc
Autor:
Lidia Martin, Jörg Trojan, Yuxin Li, Fabio Piscaglia, Marino Venerito, Renata Zaucha, Florence Marteau, P Mollon, Debashis Sarker, Ho Yeong Lim, Qing Xu, Bruno Daniele
Publikováno v:
Advances in Therapy
Introduction Cabozantinib and ramucirumab are approved for the treatment of adults with hepatocellular carcinoma (HCC) following prior sorafenib treatment; ramucirumab is restricted to use in patients with serum alpha-fetoprotein (AFP) ≥ 400 ng/mL.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89c3aa9afe58ea47cabce4fe25c8f123
https://hdl.handle.net/11585/858948
https://hdl.handle.net/11585/858948
Autor:
Peter Myrenfors, D. Mark Pritchard, Marion Feuilly, Kelly Fust, Michele Kohli, Simron Singh, Florence Marteau, Michael Maschio
Publikováno v:
PHARMACOECONOMICS
Carcinoid syndrome, a rare condition in patients with neuroendocrine tumours, characterised by flushing and diarrhoea, severely affects patients’ quality of life. The current carcinoid syndrome standard of care includes somatostatin analogues, but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e400deab76d7fb779a3a41ac069c0b8
Autor:
Ines Guerra, V. Valcheva, Bruno Daniele, Jean-Frédéric Blanc, Ghassan K. Abou-Alfa, Florence Marteau, Thomas Yau, Ann-Lii Cheng, P Mollon, Robin Kate Kelley
Publikováno v:
Advances in Therapy
Background No trials have compared cabozantinib and regorafenib for the second-line treatment of advanced hepatocellular carcinoma (HCC). Objectives Conduct a matching-adjusted indirect comparison (MAIC) of the efficacy and safety of second-line cabo
Autor:
Elvira Schmidt, Shengnan Huang, Monika Neumann, Jelena Sostar, Johanna Lister, Witold Więcek, A Vataire, Shuai Fu, Florence Marteau
Publikováno v:
Targeted Oncology
Background Cabozantinib has recently been evaluated as a first-line treatment in advanced renal cell carcinoma (aRCC). Objective To indirectly assess efficacy of cabozantinib versus standard-of-care (SoC) comparators in the first-line treatment of aR
Autor:
Gurjyot K. Doshi, Alisha Monnette, Brooke Harrow, Yunfei Wang, Christine McCarthy, Joel Wallace, Florence Marteau
Publikováno v:
Journal of Clinical Oncology. 39:e16539-e16539
e16539 Background: Checkpoint inhibitors (CPIs) are a treatment option for patients with metastatic renal cell carcinoma (mRCC), but there is limited clinical data on the efficacy of targeted therapies following CPI treatment. Cabozantinib is a tyros
Autor:
Robert J. Motzer, David Cella, Toni K. Choueiri, Youngmin Kwon, Nifasha Rusibamayila, Flavia Ejzykowicz, Marc F. Botteman, Joel Wallace, Florence Marteau, Jessica May
Publikováno v:
Journal of Clinical Oncology. 39:6567-6567
6567 Background: In CM 9ER (ClinicalTrial.gov identifier NCT03141177), N+C demonstrated significant progression-free survival gains (median: 17.0 vs. 8.3 months [mos]; hazard ratio [HR]: 0.52; P
Autor:
Christine McCarthy, Brooke Harrow, Alisha Monnette, Gurjyot K. Doshi, Joel Wallace, Florence Marteau, Yunfei Wang
Publikováno v:
Journal of Clinical Oncology. 39:293-293
293 Background: Checkpoint inhibitors (CPIs) are a treatment option for patients with metastatic renal cell carcinoma (mRCC), but there is limited clinical data on the efficacy of targeted therapies following CPI treatment. Cabozantinib is a tyrosine
Autor:
Johanna Lister, S. Pafitas, E. Schmidt, Florence Marteau, Witold Więcek, A. Zagorska, Jie Meng
Publikováno v:
Value in Health. 22:S443